|
Dr. Bennett is Senior Vice President of Research at Isis Pharmaceuticals. He is responsible for preclinical antisense drug discovery research. Dr. Bennett is one of the founding members of the company. He has been involved in the development of antisense oligonucleotides as therapeutic agents, including research on the application of oligonucleotides for inflammatory and cancer targets, oligonucleotide delivery and pharmacokinetics. He also runs the company's antisense mechanism program which is focused on the development of RNase H, RNAi, Micro-RNA and splicing. Dr. Bennett has published more than 90 papers in the field of antisense research and development and has more than 100 issued U.S. patents.
Prior to joining Isis , Dr. Bennett was Associate Senior Investigator in the Department of Molecular Pharmacology at Smith Kline and French Laboratories, GlaxoSmithKline (currently, GlaxoSmithKline).
Dr. Bennett received his B.S. degree in Pharmacy from the University of New Mexico, Albuquerque, New Mexico and his Ph.D. in Pharmacology from Baylor College of Medicine, Houston, Texas . Dr. Bennett performed his postdoctoral research in the Department of Molecular Pharmacology at Smith Kline and French Laboratories, where he studied the signal transduction pathway of leukotrienes.
| 